<DOC>
	<DOCNO>NCT01011556</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question : 1 . How teriparatide give use skin patch ( transfer skin use ViaDerm Teriparatide System ) compare teriparatide injected skin needle ( pen injector ) affect bone density ( solid porous bone ) . 2 . The safety teriparatide skin patch side effect might associate .</brief_summary>
	<brief_title>A Study Transdermal Application Teriparatide</brief_title>
	<detailed_description>Teriparatide 20 microgram ( mcg ) per day currently available subcutaneous ( SQ ) injection many patient severe osteoporosis anabolic therapy teriparatide appropriate either unwilling physically unable self-inject . The purpose Phase 2 study identify transdermal dose dos comparable teriparatide 20 mcg SQ dose pharmacodynamic ( PD ) safety standpoint use future Phase 3 study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Ambulatory , postmenopausal woman . Centrally confirm lumbar spine femoral neck bone mineral density ( BMD ) Tscore le equal 2.5 . Without language barrier , cooperative , expect return followup procedure , give informed consent inform risk , medication , procedure use study . Able use pentype injection delivery system ViaDerm Teriparatide System satisfactorily opinion investigator , help family member caregiver . Able reach telephone followup contact visit Abnormal laboratory value albumin alkaline phosphatase . Laboratory value outside range define protocol follow : Serum calcium , intact parathyroid hormone ( iPTH ) , 25 hydroxyvitamin D , 24hour urine calcium History diseases postmenopausal osteoporosis affect bone metabolism , Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis , hypoparathyroidism , hyperparathyroidism , intestinal malabsorption . History malignant neoplasms 5 year prior randomization , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . Patients carcinoma situ uterine cervix treat definitively 1 year prior entry study may randomize . Use pacemaker . Known chronic dermatological disorder , contact dermatitis History allergy sensitivity tape adhesives Patients prone bleed coagulopathies , hemophilia thrombocytopenia . Patients increase baseline risk osteosarcoma , Paget 's disease bone , unexplained elevation alkaline phosphatase ; prior external beam , implant radiation therapy involve skeleton , previous primary skeletal malignancy . Major fracture within past year femur , tibia , humerus , radius ( without ulna ) . Treatment : calcitonin 2 month prior randomization . oral , transdermal/patch , injectable estrogen , progestin , estrogen analog , estrogen agonist , estrogen antagonist , selective estrogen receptor modulators , tibolone 3 month prior randomization ; treatment intravaginal estrogen dose high 0.3 mg conjugate equine estrogen , equivalent , 3 dos per week 3 month prior randomization . androgens anabolic steroid 6 month prior randomization . fluorides 2 year prior randomization . ( Previous current use fluoridate water topical dental fluoride treatment permit . ) oral bisphosphonates 2 consecutive month 6 month prior randomization ; treatment intravenous bisphosphonates 6 month prior randomization ; treatment 1 cycle intermittent oral bisphosphonates 6 month prior randomization ; receive last cycle intermittent oral regimen le 4 week prior screen . patient receive intravenous zoledronic acid 12 month prior randomization . vitamin D great 50,000 International Units ( IU ) per week dose calcitriol vitamin D analogs agonists 6 month prior randomization . systemic corticosteroid 1 month prior randomization 30 day 1 year prior randomization . ( Ophthalmic , otic , topical , orally inhale , nasally inhale , intraarticular corticosteroid therapy may use without restriction . ) drug know significantly affect bone metabolism 6 month prior randomization . warfarin coumadin anticoagulant 1 month prior randomization . investigational drug 1 month prior entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Age Related Osteoporosis</keyword>
	<keyword>Senile Osteoporosis</keyword>
</DOC>